Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 3, 2015, Pages 589-599

  Robbins, Gregory R ^a,b   Roberts, Reid A ^a,b   Guo, Haitao ^a,b   Reuter, Kevin ^c   Shen, Tammy ^b   Sempowski, Gregory D ^d   McKinnon, Karen P ^a,b   Su, Lishan ^a,b   DeSimone, Joseph M ^b,c,e,f   Ting, Jenny P Y ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c The University of North Carolina at Chapel Hill   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e North Carolina State University   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Complement; Humanized mice; Monocytes; Nanoparticles; PEGylation; PRINT; Toxicity

Indexed keywords

ACTIVATION ANALYSIS; BODY FLUIDS; CYTOTOXICITY; HYDROGELS; IMMUNE SYSTEM; NANOPARTICLES; PRINTING; TOXICITY; VACCINES; WETTING;

COMPLEMENT; COMPLEMENT ACTIVATIONS; HUMAN PERIPHERAL BLOOD; HUMANIZED MICE; INFLAMMATORY RESPONSE; INNATE IMMUNE RESPONSE; MONOCYTES; PEGYLATION;

MAMMALS;

CD14 ANTIGEN; NANOPARTICLE; CYTOKINE; VACCINE;

ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROGEL; IMMUNOSTIMULATION; INNATE IMMUNITY; MONOCYTE; MOUSE; NANOFABRICATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SURFACE PROPERTY; ANIMAL; CHEMISTRY; CYTOLOGY; IMMUNIZATION; IMMUNOLOGY; KNOCKOUT MOUSE; NONOBESE DIABETIC MOUSE; PRECLINICAL STUDY; PROCEDURES; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD14; CELL LINE, TUMOR; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MONOCYTES; NANOPARTICLES; VACCINES;

EID: 84929152632     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.11.010     Document Type: Article

References (51)

1. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2(8):469-478.
2. Bershteyn A., Hanson M.C., Crespo M.P., Moon J.J., Li A.V., Suh H., et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release 2012, 157(3):354-365.
3. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27(23):3013-3021.
4. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470(7335):543-547.
5. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012, 30(12):1217-1224.
6. Clemente-Casares X., Tsai S., Yang Y., Santamaria P. Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?. J Mol Med 2011, 89(8):733-742.
7. Tsai S., Shameli A., Yamanouchi J., Clemente-Casares X., Wang J., Serra P., et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010, 32(4):568-580.
8. Hasan W., Chu K., Gullapalli A., Dunn S.S., Enlow E.M., Luft J.C., et al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett 2012, 12(1):287-292.
9. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
10. Naahidi S., Jafari M., Edalat F., Raymond K., Khademhosseini A., Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 2013, 166(2):182-194.
11. Love S.A., Maurer-Jones M.A., Thompson J.W., Lin Y.S., Haynes C.L. Assessing nanoparticle toxicity. Annu Rev Anal Chem (Palo Alto, Calif) 2012, 5:181-205.
12. Rolland J.P., Maynor B.W., Euliss L.E., Exner A.E., Denison G.M., DeSimone J.M. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc 2005, 127(28):10096-10100.
13. Merkel T.J., Herlihy K.P., Nunes J., Orgel R.M., Rolland J.P., DeSimone J.M. Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles. Langmuir 2010, 26(16):13086-13096.
14. Perry J.L., Herlihy K.P., Napier M.E., Desimone J.M. PRINT: A novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res 2011, 44(10):990-998.
15. Galloway A.L., Murphy A., DeSimone J.M., Di J., Herrmann J.P., Hunter M.E., et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine 2013, 9(4):523-531.
16. Amoozgar Z., Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4(2):219-233.
17. Perry J.L., Reuter K.G., Kai M.P., Herlihy K.P., Jones S.W., Luft J.C., et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 2012, 12(10):5304-5310.
18. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials 2010, 31(26):6867-6875.
19. Jones S.W., Roberts R.A., Robbins G.R., Perry J.L., Kai M.P., Chen K., et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest 2013, 123(7):3061-3073.
20. Manke A., Wang L., Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed Res Int 2013, 2013:942916.
21. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106(3):870-875.
22. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 2010, 10(3):210-215.
23. Wen H., Miao E.A., Ting J.P. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013, 39(3):432-441.
24. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
25. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012, 76(1):16-32.
26. Yazdi A.S., Guarda G., Riteau N., Drexler S.K., Tardivel A., Couillin I., et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 2010, 107(45):19449-19454.
27. Yang E.J., Kim S., Kim J.S., Choi I.H. Inflammasome formation and IL-1beta release by human blood monocytes in response to silver nanoparticles. Biomaterials 2012, 33(28):6858-6867.
28. Rice-Ficht A.C., Arenas-Gamboa A.M., Kahl-McDonagh M.M., Ficht T.A. Polymeric particles in vaccine delivery. Curr Opin Microbiol 2010, 13(1):106-112.
29. Palomaki J., Valimaki E., Sund J., Vippola M., Clausen P.A., Jensen K.A., et al. Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano 2011, 5(9):6861-6870.
30. Yang M., Flavin K., Kopf I., Radics G., Hearnden C.H., McManus G.J., et al. Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation. Small 2013, 9(24):4194-4206.
31. Neumann S., Burkert K., Kemp R., Rades T., Rod Dunbar P., Hook S. Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol Cell Biol 2014, 92(6):535-542.
32. Roberts R.A., Shen T., Allen I.C., Hasan W., DeSimone J.M., Ting J.P. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One 2013, 8(4):e62115.
33. Vaine C.A., Patel M.K., Zhu J., Lee E., Finberg R.W., Hayward R.C., et al. Tuning innate immune activation by surface texturing of polymer microparticles: the role of shape in inflammasome activation. J Immunol 2013, 190(7):3525-3532.
34. Guzmán J., Iglesias M., Riande E., Compañ V., Andrio A. Synthesis and polymerization of acrylic monomers with hydrophilic long side groups. Oxygen transport through water swollen membranes prepared from these polymers. Polymer 1997, 38:5227-5332.
35. Neun B.W., Dobrovolskaia M.A. Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol 2011, 697:237-245.
36. Zhang L., Jiang Q., Li G., Jeffrey J., Kovalev G.I., Su L. Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2(-)/(-)gamma C(-)/(-) mice in vivo. Blood 2011, 117(23):6184-6192.
37. Jiang Q., Zhang L., Wang R., Jeffrey J., Washburn M.L., Brouwer D., et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood 2008, 112(7):2858-2868.
38. Bility M.T., Zhang L., Washburn M.L., Curtis T.A., Kovalev G.I., Su L. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat Protoc 2012, 7(9):1608-1617.
39. Zhang L., Kovalev G.I., Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007, 109(7):2978-2981.
40. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009, 61(13):1177-1188.
41. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249(4975):1431-1433.
42. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1(5):398-401.
43. Lee H.K., Dunzendorfer S., Soldau K., Tobias P.S. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006, 24(2):153-163.
44. Scott P., Ma H., Viriyakosol S., Terkeltaub R., Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177(9):6370-6378.
45. Power C.P., Wang J.H., Manning B., Kell M.R., Aherne N.J., Wu Q.D., et al. Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD14 and TLR-2. J Immunol 2004, 173(8):5229-5237.
46. Sahu A., Lambris J.D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001, 180:35-48.
47. Gross O., Thomas C.J., Guarda G., Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011, 243(1):136-151.
48. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6(4):715-728.
49. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012, 52:481-503.
50. Triglia R.P., Linscott W.D. Titers of nine complement components, conglutinin and C3b-inactivator in adult and fetal bovine sera. Mol Immunol 1980, 17(6):741-748.
51. Leijh P.C., van den Barselaar M.T., van Zwet T.L., Daha M.R., van Furth R. Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest 1979, 63(4):772-784.